2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word(s): Personnel Ad hoc announcement pursuant to Art. 53 LR Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board of Directors of his intention to step down as a Non-Executive member of the Board of Directors, effective December 31, 2021. Ulrich Köstlin, Chairman of Newron, commented: 'The Board of Directors and I would like to thank Bob for his dedication and commitment to Newron since he joined the Board in 2013. During his time at Newron, amongst other milestones achieved, we have seen the approval and launch of our Parkinson's disease product Xadago(R) in key territories including the EU, the USA and Japan, and the advancement of our pipeline product Evenamide into potentially pivotal studies in patients suffering from schizophrenia. He leaves with our sincere thanks and best wishes for the future.' Robert Leslie Holland is a member of the Company's R&D Committee. At this time, Newron does not anticipate making any Non-Executive Director appointments. About Newron Pharmaceuticals For more information Newron UK/Europe End of ad hoc announcement |
| Language: | English |
| Company: | Newron Pharmaceuticals SpA |
| Via Antonio Meucci 3 | |
| 20091 Bresso | |
| Italy | |
| E-mail: | info@newron.com |
| Internet: | www.newron.com |
| ISIN: | IT0004147952 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1253502 |
| End of Announcement | EQS Group News Service |
|
|
1253502 01-Dec-2021 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
